Applied Imaging, of Santa Clara, Calif., closed a private financing round of $4.6 million. Lead investors were Allen and Co., of New York, and New Enterprise Associates, of San Francisco.

Biopool International Inc., of Ventura, Calif., received FDA approval to market five new chemistry reagent systems.

Cambridge Biotech Corp., of Worcester, Mass., got FDA approval of its product license application for HTLV-I immunoassay.

Cygnus Inc., of Redwood City, Calif., registered to sell 2 million shares in a public offering in which 20 percent of the shares will be offered outside North America. The company's efforts are geared primarily toward development of a glucose monitoring device, transdermal drug delivery and mucosal delivery.

Immucor Inc., of Norcross, Ga., began clinical trials of its automated blood bank system, the ABS 2000.

Incstar Corp., of Stillwater, Minn., launched its second- generation Parathyroid Hormone-related Protein assay.

International Murex Technologies Corp., of Atlanta, got premarket clearance for five latex agglutination tests. The tests will help detect antibodies to infectious mononucleosis, group A streptococcus, rheumatoid arthritis (two tests), and to help detect C-reactive protein, which relates to tissue injury.

Metra Biosystems Inc., of Mountain View, Calif., said data from a French study suggests its Pyrilinks-D assay can be used to assess increased risk of hip fracture. The assay, under review by the FDA, measured levels of free deoxypyridinoline. The levels were higher in elderly women who later experienced a hip fracture by a statistically significant amount. Metra also released results of an internal study that showed little day-to-day variation in biochemical bone markers as measured by Pyrilinks assays. Finally, the company said use of the assay in combination with ultrasound measurement of bone mineral density can provide increased precision in screening for osteopenia.

Molecular Biosystems Inc., of San Diego, received approval to begin Phase III tests of its intravenous ultrasound contrast agent, FS069.

Neose Technologies Inc., of Philadelphia, and Bracco Research USA, a unit of Italy-based Bracco S.p.A., are collaborating on research into a class of imaging agents that consist of complex carbohydrates attached to diagnostically active compounds.

Sonus Pharmaceuticals Inc., of Bothell, Washington, which is developing contrast agents for use in ultrasound imaging, filed for an initial public offering of up to 2.5 million shares at $10 to $12 per share. New York-based firms Hambrecht & Quist Inc. and UBS Securities Inc. are underwriting the offering.

(c) 1997 American Health Consultants. All rights reserved.